UBS Group
ODTX

UBS Group’s Odyssey Therapeutics ODTX Stock Holding History

UBS Group’s Portfolio ODTX Stock Details ODTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.29M Buy
+68,758
New +$1.21M ﹤0.01% 5512

Other funds holding ODTX

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $2.4B AUM 7.07% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

UBS Group's ODTX Position: Q2 2026 in Review

UBS Group opened a new position in Odyssey Therapeutics (ODTX) in Q2 2026: 68,758 shares worth $1.29M. The stake represents ﹤0.01% of the portfolio and ranks #5512 among its holdings.

50 funds tracked by Wall St. Rank hold ODTX as of Q2 2026.

  • UBS Group held 68,758 shares of Odyssey Therapeutics worth $1.29M as of Q2 2026.
  • Odyssey Therapeutics was a new UBS Group position in Q2 2026.
  • Odyssey Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5512 holding.
  • 50 funds tracked by Wall St. Rank held Odyssey Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.